Literature DB >> 25239414

Comparison study of the eosin-5'-maleimide binding test, flow cytometric osmotic fragility test, and cryohemolysis test in the diagnosis of hereditary spherocytosis.

Sang Hyuk Park1, Chan-Jeoung Park2, Bo-Ra Lee1, Young-Uk Cho1, Seongsoo Jang1, Nayoung Kim3, Kyung-Nam Koh4, Ho-Joon Im4, Jong-Jin Seo4, Eun Sil Park5, Ji Won Lee6, Keon Hee Yoo7, Hye Lim Jung7.   

Abstract

OBJECTIVES: Current guidelines recommend the eosin-5'-maleimide (EMA) binding test and cryohemolysis test for screening for hereditary spherocytosis (HS), and the flow cytometric osmotic fragility (FC OF) test was recently developed to replace the classic OF test. We evaluatedthe performance of the EMA binding test, FC OF test, cryohemolysis test, and the hemoglobin (Hb)/mean corpuscular hemoglobin concentration (MCHC) ratio in the diagnosis of HS and assessed whether these tests reflect the clinical severity of HS.
METHODS: A total of 153 patients with anemia (33 with HS, 40 with autoimmune hemolytic anemia, 40 with anemia of chronic disease, and 40 with iron deficiency anemia [IDA]) and 140 healthy controls were enrolled, and the performance of the three tests was evaluated.
RESULTS: Both the EMA binding test (area under the curve [AUC], 0.996) and the FC OF test (AUC, 0.992) performed satisfactorily, but the cryohemolysis test (AUC, 0.723) performed significantly worse because of false positivity in patients with IDA. The Hb/MCHC ratio (P < .001) was able to reflect the clinical severity of HS.
CONCLUSIONS: Our results demonstrate that both the EMA binding and FC OF tests are useful as screening tests for the diagnosis of HS, but the cryohemolysis test has limited use due to its false positivity in IDA, with the Hb/MCHC ratio the most useful parameter for assessing the clinical severity of HS. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Cryohemolysis test; EMA binding test; Flow cytometric osmotic fragility test; Hb/MCHC; Hereditary spherocytosis

Mesh:

Substances:

Year:  2014        PMID: 25239414     DOI: 10.1309/AJCPO7V4OGXLIIPP

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

1.  Flow Cytometric Eosin-5'-Maleimide Test is a Sensitive Screen for Hereditary Spherocytosis.

Authors:  Preethi S Chari; Sujay Prasad
Journal:  Indian J Hematol Blood Transfus       Date:  2017-12-06       Impact factor: 0.900

2.  A novel SPTB mutation causes hereditary spherocytosis via loss-of-function of β-spectrin.

Authors:  Shan Li; Ping Guo; Leyuan Mi; Xiaojing Chai; Kewang Xi; Ting Liu; Li Lu; Juan Li
Journal:  Ann Hematol       Date:  2022-01-31       Impact factor: 3.673

Review 3.  Korean clinical practice guidelines for the diagnosis of hereditary hemolytic anemia.

Authors:  Hee Won Chueh; Sang Mee Hwang; Ye Jee Shim; Jae Min Lee; Hee Sue Park; Joon Hee Lee; Youngwon Nam; Namhee Kim; Hye Lim Jung; Hyoung Soo Choi
Journal:  Blood Res       Date:  2022-05-20

Review 4.  Old and new insights into the diagnosis of hereditary spherocytosis.

Authors:  Olga Ciepiela
Journal:  Ann Transl Med       Date:  2018-09

5.  Mean corpuscular volume of control red blood cells determines the interpretation of eosin-5'-maleimide (EMA) test result in infants aged less than 6 months.

Authors:  Olga Ciepiela; Anna Adamowicz-Salach; Weronika Bystrzycka; Jan Łukasik; Iwona Kotuła
Journal:  Ann Hematol       Date:  2015-04-25       Impact factor: 3.673

6.  Stability of eosin-5'-maleimide dye used in flow cytometric analysis for red cell membrane disorders.

Authors:  Simmi Mehra; Neetu Tyagi; Pranav Dorwal; Amit Pande; Dharmendra Jain; Ritesh Sachdev; Vimarsh Raina
Journal:  Blood Res       Date:  2015-06-25

7.  Cryohemolysis, erythrocyte osmotic fragility, and supplementary hematimetric indices in the diagnosis of hereditary spherocytosis.

Authors:  Ledesma Achem Miryam Emilse; Haro Cecilia; Terán Magdalena María; Mónaco María Eugenia; Issé Blanca Alicia; Sandra Stella Lazarte
Journal:  Blood Res       Date:  2018-03-27

8.  Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis.

Authors:  Shiyue Ma; Lingjian Tang; Chaoli Wu; Hui Tang; Xue Pu; Jinhong Niu
Journal:  Appl Bionics Biomech       Date:  2022-01-28       Impact factor: 1.781

9.  Epidemiological Study of Hereditary Hemolytic Anemia in the Korean Pediatric Population during 1997-2016: a Nationwide Retrospective Cohort Study.

Authors:  Ye Jee Shim; Hye Lim Jung; Hee Young Shin; Hyoung Jin Kang; Jung Yoon Choi; Jeong Ok Hah; Jae Min Lee; Young Tak Lim; Eu Jeen Yang; Hee Jo Baek; Hyoung Soo Choi; Keon Hee Yoo; Jun Eun Park; Seongkoo Kim; Ji Yoon Kim; Eun Sil Park; Ho Joon Im; Hee Won Chueh; Soon Ki Kim; Jae Hee Lee; Eun Sun Yoo; Hyeon Jin Park; Jun Ah Lee; Meerim Park; Hyun Sik Kang; Ji Kyoung Park; Na Hee Lee; Sang Kyu Park; Young Ho Lee; Seong Wook Lee; Eun Jin Choi; Seom Gim Kong
Journal:  J Korean Med Sci       Date:  2020-08-24       Impact factor: 2.153

10.  Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry.

Authors:  Navavee Uman; Sirorat Kobbuaklee; Patsita Kansuwan; Phandee Watanaboonyongcharoen; Chantana Polprasert
Journal:  Hematol Rep       Date:  2022-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.